Sor102 ((full)) Guide

Recent studies suggest that blocking both TNF and IL-23 is more effective than blocking either one alone. SOR102 does this within a single molecule. Future Outlook

SOR102: A Breakthrough in Oral Biologics for Ulcerative Colitis

is an investigational, orally delivered biologic currently in clinical development for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) . Developed by Sorriso Pharmaceuticals, it represents a potential paradigm shift in how advanced therapies are administered to patients with chronic gastrointestinal inflammation. What is SOR102? sor102

Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling"

Patients receiving SOR102 twice daily (BID) showed notable improvements over 6 weeks: Recent studies suggest that blocking both TNF and

Recent Phase 1b clinical data, published in journals like The Lancet Gastroenterology & Hepatology , highlight three critical advantages of SOR102:

: Briefly introduce what sor102 is about. Why it Matters: Breaking the "Therapeutic Ceiling" Patients

:

:

If "sor102" is a course or educational topic, here's a basic outline:

The molecule features a "trypsin-labile linker" that allows the two components to stay together through the stomach but separate once they reach the small intestine, providing localized therapy directly at the site of disease while minimizing absorption into the bloodstream. Clinical Trial Results